European Union awards Meinox with Horizon 2020 SME Instrument
Meinox announces the support of the highly competitive European Union’s Horizon 2020 research and innovation program for Small to Medium-Sized Enterprise (SME) for the marketing of MEIS inhibitors. The Meinox develops next generation therapeutics to fight cancer by novel small molecule MEIS inhibitors. In phase 1, Meinox is awarded EUR 50'000 and mentored by EU industry experts to compile a feasibility study for a phase 2 proposal (upto 2.5M Euros). The team thanks the European Commission for the award received.
The European Union’s Horizon 2020 research and innovation program supports breakthrough innovation projects with a market-creating potential. The SME instrument boosts fast company growth and market-creating innovation thanks to staged funding and ramped up business acceleration services.
Horizon 2020 SME Instrument Phase I grant number: 888430